GLP-1 medications are FDA-approved for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in people with obesity
Emerging research has identified GLP-1 receptor expression in kidney tissue and the urinary tract, suggesting that semaglutide may have direct effects on urinary tract biology that we are only beginning to understand
Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al
Semaglutide GLP-1 for weight loss is available at Noor Medical Spa
Based on past usage and expenditure, a 1% rise in GLP-1 weight loss utilization among an insured population would result in an additional $14.50 per member per month cost for most self-insured employers, which would be over a 5% increase in their total drug spend budget
This program may include assistance with blood glucose meters, test strips, and other related diabetes supplies